Rhumbline Advisers Purchases 69,832 Shares of Amyris, Inc. (NASDAQ:AMRS)

Rhumbline Advisers increased its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 42.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,745 shares of the biotechnology company’s stock after acquiring an additional 69,832 shares during the quarter. Rhumbline Advisers’ holdings in Amyris were worth $3,826,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMRS. The PNC Financial Services Group Inc. bought a new position in shares of Amyris during the 1st quarter worth approximately $36,000. tru Independence LLC bought a new position in shares of Amyris during the 2nd quarter worth approximately $59,000. Endurance Wealth Management Inc. raised its stake in shares of Amyris by 137,400.0% during the 2nd quarter. Endurance Wealth Management Inc. now owns 5,500 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 5,496 shares in the last quarter. Glassman Wealth Services grew its position in Amyris by 85.7% during the 2nd quarter. Glassman Wealth Services now owns 6,500 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Bellwether Advisors LLC purchased a new stake in Amyris during the 1st quarter worth approximately $193,000. Hedge funds and other institutional investors own 44.16% of the company’s stock.

AMRS has been the topic of several research analyst reports. Roth Capital dropped their target price on shares of Amyris from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 6th. Oppenheimer boosted their target price on shares of Amyris from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Friday, August 6th. HC Wainwright dropped their price objective on shares of Amyris from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, August 6th. HSBC assumed coverage on shares of Amyris in a report on Tuesday, June 1st. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Amyris from a “sell” rating to a “hold” rating in a report on Friday, August 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.39.

Shares of NASDAQ AMRS opened at $13.74 on Friday. The company’s fifty day moving average price is $14.22 and its 200 day moving average price is $15.45. Amyris, Inc. has a 1 year low of $1.88 and a 1 year high of $23.42. The company has a market capitalization of $4.09 billion, a PE ratio of -6.57 and a beta of 1.13.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $52.32 million for the quarter, compared to analysts’ expectations of $53.73 million. As a group, equities analysts predict that Amyris, Inc. will post -1.19 earnings per share for the current fiscal year.

In other Amyris news, insider Nicole Kelsey sold 3,483 shares of the company’s stock in a transaction on Thursday, September 2nd. The shares were sold at an average price of $14.86, for a total transaction of $51,757.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eduardo Alvarez sold 17,605 shares of the company’s stock in a transaction on Thursday, September 2nd. The stock was sold at an average price of $14.86, for a total transaction of $261,610.30. The disclosure for this sale can be found here. Insiders have sold 141,745 shares of company stock valued at $2,170,058 over the last 90 days. 36.30% of the stock is currently owned by company insiders.

Amyris Company Profile

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Featured Article: Discover Your Risk Tolerance

Want to see what other hedge funds are holding AMRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amyris, Inc. (NASDAQ:AMRS).

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.